Genmab — Maj 2014
-
den bør åbne i 176-187 intervallet som er -10-15%
-
du er ofte savnet plex
-
-
Ja

-
Mon ikke Jan bliver fanget af Medwatch senere
-
er der nogen der kan forklare mig hvorfor det er så forfærdeligt med lukningen af Arzerra i (DLBCL) når ikke engang Rituxan/MabThera) i kombination med kemoterapi til behandling af recidiverende eller refraktært diffust storcellet B-celle lymfom (DLBCL) er godkendt i indikationen ?????
-
Celsius Rituxan sælger for over 1 mia. $ om året i den her indikation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind